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Many patients with relapsed or refractory acute myeloid leukemia (AML) do not receive allogeneic
hematopoietic cell transplantation (alloHCT) because they are unable to achieve a complete remission (CR)
after reinduction chemotherapy. Starting in January 2003, we prospectively assigned patients with AML
with high-risk clinical features to preemptive alloHCT (p-alloHCT) as soon as possible after reinduction
chemotherapy. High-risk clinical features were associated with poor response to chemotherapy: primary
induction failure, second or greater relapse, and ﬁrst CR interval <6 months. We hypothesized that any
residual disease would be maximally reduced at the time of transplant, resulting in the best milieu and
most lead time for developing a graft-versus-leukemia effect and in improved long-term overall survival
(OS) without excess toxicity. This analysis studied the effect of transplant timing on p-alloHCT in 30 patients
with high-risk clinical features of 156 consecutive AML patients referred for alloHCT. We compared early p-
alloHCT within 4 weeks of reinduction chemotherapy before count recovery with late p-alloHCT 4 weeks
after reinduction chemotherapy with count recovery. OS and progression-free survival (PFS) at 2 years were
not signiﬁcantly different for early versus late p-alloHCT (OS 23% versus 33%, respectively, P > .1; PFS 18%
versus 22%, respectively, P > .1). Day 100 and 1-year transplant-related mortality were similar (33.3% versus
22.2%, P > .1; 44.4% versus 42.9%, P > .1, respectively). Preemptive alloHCT allowed 30 patients to be
transplanted who would normally not receive alloHCT. Clinical outcomes for early p-alloHCT are similar to
those for late p-alloHCT without excess toxicity. Early p-alloHCT is a feasible alternative to late p-alloHCT
for maximizing therapy of AML that is poorly responsive to induction chemotherapy.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (alloHCT)
for poor-prognosis acute myeloid leukemia (AML) has been
performed after achieving a complete remission (CR) to
consolidate a patient’s response to chemotherapy and
prevent future relapse. Many patients, however, will not
receive an alloHCT because they are unable to achieve a CR
because of chemotherapy resistant or rapidly progressiveedgments on page 1374.
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14.05.013disease. The overall clinical beneﬁt of alloHCT in patients not
in CR is uncertain because any nascent graft-versus-
leukemia effects may be overtaken by expanding residual
disease and gains from disease control may be outweighed
by transplant-related complications.
Residual leukemia is a contraindication to alloHCT in
some transplant centers. An alternative approach is to
perform alloHCT preemptively (p-alloHCT) after induction
chemotherapy. In this setting, any residual disease has been
maximally treated, allowing the donor graft the best chance
to initiate a graft-versus-leukemia effect and overcome the
kinetics of disease progression. Because alloHCT requires
advance planning, it is often not possible to make decisions
about proceeding with p-alloHCT based on a late restaging
pretransplant bone marrow biopsy. Therefore, starting inTransplantation.
Table 1
Reasons Patients Did Not Receive alloHCT
Reason n (%)
Rapid disease progression 19 (23)
Patient refusal 15 (18)
Reinduction chemotherapyerelated toxicity 14 (17)
Received an autologous BMT 11 (13)
Received transplant at another facility 7 (8)
Comorbidities 4 (5)
Stable disease 4 (5)
No donor 3 (4)
Financial issues 4 (5)
Psychosocial issues 2 (2)
Age 1 (1)
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Marrow Transplant and Leukemia services made a pro-
grammatic decision to prospectively treat all AML patients
with high-risk clinical features predictive of not achieving a
CR with p-alloHCT. These high-risk clinical features were
deﬁned as primary induction failure, second or greater
relapse, and ﬁrst CR interval <6 months. Because alloHCT
soon after induction chemotherapy may be associated with
fatal toxicity, we analyzed the effect of p-alloHCT timing on
safety, feasibility, and clinical effect of alloHCT in 30 AML
patients with high-risk clinical features.
METHODS
Disease, Response, and Treatment Group Deﬁnitions
AML was diagnosed according to the World Health Organization and
French-American-British classiﬁcation schemes [1-3]. Cytogenetic risk was
categorized according to Eastern Cooperative Oncology and Southwest
Oncology Group criteria: good risk (inv16, t[8;21], t[15;17]), poor risk (5/
del[5q], 7/del[7q], inv[3q], abn11q, 20q or 21q, del[9q], t[6;9], t[9;22],
abn17p, and complex karyotype deﬁned as three or more abnormalities),
and intermediate risk (other and normal karyotypes) [4].
Early p-alloHCT was performed within 4 weeks of induction or rein-
duction chemotherapy before count recovery regardless of restaging bone
marrow histopathology. Late p-alloHCT was performed after count recovery
and >4 weeks after prior chemotherapy. Count recovery was deﬁned as an
absolute neutrophil count >1  109/L and a platelet count >100  109/L.
Bone marrow biopsies were performed 2 weeks before graft infusion
to assess disease status. CR was deﬁned as a normocellular bone marrow
containing <5% blasts with count recovery. A hypoplastic bone marrow was
deﬁned as <20% bone marrow cellularity with <5% blasts. A refractory bone
marrow was deﬁned as 5% blasts, regardless of cellularity.
Patient Population
From January 2003 to March 2008, 156 consecutive adult AML patients
were referred to the Roswell Park Cancer Institute Blood and Marrow
Transplant program for alloHCTevaluation. Eighty-four of 156 patients (54%)
did not receive alloHCT for reasons presented in Table 1. Seventy-two of 156
patients (46%) received alloHCT; 30 of these 72 were at high risk for not
achieving a CR after induction chemotherapy based on the following risk
factors: primary induction failure, beyond ﬁrst relapse, or remission interval
<6 months. In this report, these patients, who were at high risk for not
achieving a CR after reinduction chemotherapy, are referred to as having
high-risk clinical features. This is in distinction to poor-risk cytogenetic
features such as those speciﬁed by Eastern Cooperative Oncology and
Southwest Oncology Group criteria. Primary induction failure was deﬁned
as being unable to achieve a CR after 1 cycle of induction chemotherapy.
Duval score for refractory AML was calculated as previously described [5].
Treatment
AML induction, consolidation, and reinduction chemotherapy were
performed according to available clinical trials or institutional standards.
Preemptive alloHCT was deﬁned as alloHCT performed as soon as possible
after reinduction chemotherapy when AML was in a maximally reduced
state. Preemptive alloHCT was prospectively planned for all patients with
AML with high-risk features as deﬁned above in Patient Population.
Transplant conditioning regimens (myeloablative with busulfan/cyclo-
phosphamide or etoposide/cyclophosphamide/total body irradiation or
reduced intensity with ﬂudarabine/melphalan or ﬂudarabine/cyclophos-
phamide) were assigned based on baseline characteristics such as age,
Karnofsky performance status, comorbidities, disease risk, and HLA
matching. Acute graft-versus-host disease (GVHD) prophylaxis was
assigned as tacrolimus only, tacrolimus/mycophenolate mofetil or a
calcineurin inhibitor (tacrolimus or cyclosporine)/methotrexate  other
(methylprednisolone or mycophenolate mofetil) [6]. Tacrolimus doses were
adjusted to maintain blood levels of 5 to 10 ng/dL during the ﬁrst 100 days
and then tapered off in the absence of GVHD by 6 months. Mycophenolate
mofetil was discontinued at day þ60 in the absence of GVHD.
Statistical Analysis
The Roswell Park Cancer Institute Institutional Review Board approved
this retrospective analysis. The null hypothesis for the study stated that early
p-alloHCT was not associated with a decrease in overall survival (OS) or
increase in transplant-related mortality (TRM). The Pearson chi-square test
or Fisher’s exact text was used for univariate comparisons of categorical
variables, and the ANOVA F-test was used for comparisons of continuousvariables. OS was deﬁned as the time from the date of blood and marrow
transplant (BMT) (day 0) to the date of death due to any cause. Progression-
free survival (PFS) was deﬁned as the time from the date of BMT to ﬁrst
disease progression after BMT or death due to any cause. Patients who did
not experience these events were censored at the time of last follow-up.
Kaplan-Meier survival curves were constructed, and the difference was
tested by the log-rank statistic. All statistical analyses were performed with
SPSS version 21 (IBM, Armonk, NY) with 2-sided Type I error rate at .05.RESULTS
Patient and Disease Characteristics
Characteristics for 72 patients receiving alloHCT are
presented in Table 2. Thirty of these 72 patients (42%) were
identiﬁed as having high-risk clinical features predictive for
not achieving CR after chemotherapy and thus were pro-
spectively assigned to p-alloHCT after reinduction chemo-
therapy. Twenty-one of these patients with high-risk clinical
features received early p-alloHCT. The other 9 received late
p-alloHCT because of delays in going to transplant for
logistical reasons. Restaging bone marrow biopsies per-
formed after reinduction and immediately before transplant
demonstrated hypoplasia (n¼ 11), refractory disease (n ¼ 9),
and CR (n¼ 1) in the 21 patients receiving early p-alloHCT. In
the 9 patients receiving late p-alloHCT, restaging pretrans-
plant bone marrow biopsies demonstrated hypoplasia
(n ¼ 2) and refractory disease (n ¼ 7). Forty-two of the 72
patients (58%) who did not have high-risk clinical features
achieved a CR with count recovery before alloHCT and
received a standard alloHCT. Patient dispositions are shown
in Figure 1.
The following analysis focuses on the 30 high-risk AML
patients who received either early (n ¼ 21) or late (n ¼ 9)
p-alloHCT. A higher proportion of the early versus
late p-alloHCT group received 1 or more reinduction
regimens (95% versus 66%). Gemtuzumab ozogamicin use
was more frequent in the early versus late p-alloHCT group
(57% versus 22%, respectively, P ¼ .09). A lower proportion of
patients in the early versus late p-alloHCT group had
leukemia with adverse cytogenetics. Both early and late
p-alloHCT groups had similar distributions in Duval score,
age, presenting WBC counts, French-American-British clas-
siﬁcation, history of prior transplant, and bone marrow
status before alloHCT. Compared with late p-alloHCT, a
greater proportion of patients receiving early p-alloHCT had
a Karnofsky performance status 80 (95% versus 67%) at the
time of transplant. A greater proportion of early versus late
p-alloHCT patients received reduced-intensity conditioning
regimens before alloHCT (95% versus 78%). A higher pro-
portion of patients in the early versus late p-alloHCT group
received a graft from a<10/10 HLAmatched unrelated donor
Table 2
Patient Characteristics
Characteristic High-Risk Disease Standard-Risk Disease
Early p-alloHCT (n ¼ 21) Late p-alloHCT (n ¼ 9) Standard alloHCT (n ¼ 42)
Age, yr
18-40 4 (19) 2 (22) 14 (33)
41-60 13 (62) 6 (67) 22 (52)
61þ 4 (19) 1 (11) 6 (14)
KPS
90 1 (5) 3 (33) 20 (48)
80 20 (95) 6 (67) 22 (52)
FAB classiﬁcation
M0 0 (0) 1 (11) 6 (14)
M1 6 (29) 2 (22) 8 (19)
M2 9 (43) 1 (11) 13 (31)
M4 3 (14) 2 (22) 8 (19)
M5 2 (10) 2 (22) 6 (14)
M6 1 (5) 1 (11) 0 (0)
NOS 0 (0) 0 (0) 1 (2)
WBC at diagnosis
30  109/L 9 (43) 2 (22) 10 (24)
<30  109/L 12 (57) 7 (78) 32 (76)
Cytogenetics
Good 2 (10) 0 (0) 0 (0)
Intermediate 16 (76) 6 (67) 22 (52)
Poor 3 (14) 3 (33) 20 (48)
De novo versus secondary AML
De novo 17 (81) 9 (100) 30 (71)
Secondary 4 (19) 0 (0) 12 (29)
Induction chemotherapy regimen
7 þ 3 þ other 9 (43) 4 (44) 25 (60)
ATO* þ AraC þ Ida* 8 (38) 5 (56) 13 (31)
AraC þ Ida 3 (14) 0 (0) 4 (10)
Other 1 (5) 0 (0) 0 (0)
First reinduction chemotherapy regimen
None 1 (5) 3 (33) 32 (76)
AraC þ gemtuzumab 7 (33) 1 (11) 0 (0)
AraC þ anthracycline  VP16 8 (38) 3 (33) 2 (5)
AraC 2 (10) 0 (0) 5 (12)
Mito þ VP16 1 (5) 0 (0) 2 (5)
Other 2 (10) 2 (22) 1 (2)
No. reinduction chemotherapy regimens
0 1 (5) 3 (33) 32 (76)
1 12 (57) 2 (22) 9 (21)
2-4 8 (38) 4 (44) 1 (2)
Pre-alloHCT gemtuzumab
Yes 12 (57) 2 (22) 0 (0)
No 9 (43) 7 (78) 42 (100)
AlloHCT regimen
Myeloablative conditioning 1 (5) 2 (22) 18 (43)
Reduced-intensity conditioning 20 (95) 7 (78) 24 (57)
Donor type
Related 8 (38) 4 (44) 20 (48)
Unrelated 13 (62) 5 (56) 22 (52)
Graft source
Bone marrow  peripheral blood 1 (5) 1 (11) 9 (21)
Peripheral blood 20 (95) 8 (89) 33 (79)
HLA match
10/10 14 (67) 9 (100) 39 (93)
9/10 7 (33) 0 (0) 3 (7)
Sex match
Match 13 (62) 8 (89) 22 (52)
Mismatch 8 (38) 1 (11) 20 (48)
Prior autologous HCT
Yes 3 (14) 0 (0) 2 (5)
No 18 (86) 9 (100) 40 (95)
Restaging bone marrow status before alloHCT
Hypoplasticy 11 (52) 5 (56) 0 (0)
Refractory diseasez 9 (43) 4 (44) 0 (0)
CR 1 (5) 0 (0) 42 (100)
GVHD prophylaxis
TAC or CSA/MTX  other 11 (52) 8 (9) 29 (69)
TAC/MMF 6 (29) 1 (11) 13 (31)
TAC/MTX 5 (24) 4 (44) 18 (43)
FEV1, %
Median (range) 91.9 (61.6-119.4) 87 (61-130) 99 (48-124)
(Continued on next page)
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Table 2
(continued)
Characteristic High-Risk Disease Standard-Risk Disease
Early p-alloHCT (n ¼ 21) Late p-alloHCT (n ¼ 9) Standard alloHCT (n ¼ 42)
DLCO corrected, %
Median (range) 79 (42.9-113) 76 (56-106) 80 (38-110)
Ejection fraction, %
Median (range) 56 (50-75) 60 (55-67) 60 (44-75)
Duval score
0 2 (9.5) 1 (11.1) NA
1 6 (26.8) 3 (33.3) NA
2 8 (38.1) 3 (33.3) NA
3 5 (23.8) 2 (22.2) NA
7þ3 indicates cytarabine x 7 days and daunorubicin x 3 days; AlloHCT, allogeneic hematopoietic cell transplant; AML, acute myeloid leukemia; AraC, cytarabine;
ATO, arsenic trioxide; AutoHCT, autologous hematopoietic cell transplant; BMT, blood and marrow transplantation; CR, complete remission; CSA, cyclosporine;
FAB, French American British; HLA, human leukocyte antigen; Ida, idarubicin; KPS, Karnofsky performance score; Mito, mitoxantrone; MMF, mycophenolate
mofetil; MTX, methotrexate (25 mg/m2 or 7.5 mg/m2 total); p-alloHCT, pre-emptive alloHCT; NA, not applicable; TAC, tacrolimus; VP16, etoposide; WBC, white
blood cell; * ATO was given as part of a phase 1 clinical trial [18], y hypoplastic was deﬁned as <20% bone marrow cellularity with <5% blasts; z refractory bone
marrow was deﬁned as 5% blasts, regardless of cellularity.
Values are number of cases, with percents in parentheses, unless otherwise noted.
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match were similar in both groups.
Clinical Outcomes
The median follow-up was 30 (range, 13 to 70) months.
OS (23% versus 33%, P > .1, Figure 2A) and PFS (18% versus
22%, P > .1, Figure 2B) were not signiﬁcantly different at
2 years between AML patients with high-risk clinical
features who received early versus late p-alloHCT. Three-
year OS by low (0 to 1), intermediate (2), or high (3)
Duval score was 46%, 9%, and 0%, respectively, for all 30 AML
patients with high-risk clinical features. As expected, OS and
PFS at 2 years were better for patients receiving standardFigure 1. Patient dispositions and restagingalloHCT (61% and 59%, respectively). TRM was not
signiﬁcantly different between AML patients with high-risk
clinical features who received early versus late p-alloHCT at
100 days (33% versus 22%, P> .1) and 1 year (44% versus 43%,
P > .1). TRM for early p-alloHCT was associated with infec-
tious causes in 3 of 7 patients who died before 100 days,
with no infectious deaths in an additional 2 TRM deaths
between 100 days and 1 year post-alloHCT. TRM for late p-
alloHCT was associated with infectious causes in 2 patients
who died before 100 days, with no infectious deaths in the 1
additional TRM death between 100 days and 1 year post-
alloHCT. All TRM due to infectious causes occurred within
the ﬁrst 100 days.bone marrow status before alloHCT.
Figure 2. (A) Overall survival (OS) for patients receiving early or late pre-
emptive alloHCT (p-alloHCT) stratiﬁed by pre-transplant bone marrow status.
There was no signiﬁcant difference in OS for patients with high risk AML
treated with early or late p-alloHCT (P > .1). OS was better in patients with
standard risk AML receiving standard alloHCT compared to those with high
risk AML due to the majority of patients who achieved CR before transplant.
HE, High clinical risk AML early p-alloHCT; HL, High clinical risk AML late p-
alloHCT; NS, not signiﬁcant; SS, Standard risk AML standard alloHCT. (B)
Progression free survival (PFS) for patients receiving early or late preemptive
alloHCT (p-alloHCT) stratiﬁed by pre-transplant bone marrow status. There
was no signiﬁcant different in PFS for patients with high risk AML treated with
early or late p-alloHCT (P > .1). PFS was better in patients with standard risk
AML receiving standard alloHCT compared to high risk AML due to the ma-
jority of patients who achieved CR before transplant. HE, High clinical risk AML
early alloHCT; HL, High clinical risk AML late p-alloHCT; NS, not signiﬁcant; SS,
Standard risk AML standard alloHCT.
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A hypoplastic or refractory bone marrow would normally
preclude alloHCT because of the uncertain prognosis. The 30
AML patients with high-risk clinical features in this study
therefore would normally not undergo alloHCT. At our
institute, however, all AML patients at high risk for incom-
plete remissions over this time frame were prospectively
planned for alloHCT regardless of bone marrow status. The
median time between the end of the last reinduction therapy
and infusion of the donor graft was signiﬁcantly shorter in
the early versus late p-alloHCT group (33 days versus
65 days, P < .01).
DISCUSSION
AlloHCT after induction chemotherapy for patients with
refractory AML is controversial because of the uncertain
clinical beneﬁt and potential excess toxicity. We demon-
strate that early p-alloHCT before count recovery in AML
patients with high-risk clinical features associated with not
achieving a CR after induction chemotherapy has acceptable
mortality and results in clinical outcomes not signiﬁcantly
different from late p-alloHCT patients transplanted after
count recovery. Large registry studies of alloHCT for residual
AML have reported OS rates of 16% to 19% at 3 years and 10%
to 27% at 5 years [5,7-9]. These outcomes are comparable
with our observed outcomes but should be interpreted
cautiously because of differences in patient selection, con-
ditioning regimens, and supportive care. The early and late
p-alloHCT subgroups were signiﬁcantly different in the
timing of alloHCT. Certain disease-related factors may have
contributed to better disease control or response in the early
p-alloHCT group, such as a higher proportion of patients
being treated with gemtuzumab ozogamicin and a lower
proportion of patients with WBC < 30  109/L or adverse
cytogenetics [10-15]. Although these disease-related factors
predict the likelihood of achieving and maintaining a CR
after chemotherapy, their importance may be outweighed
by those predicting for higher TRM in the early p-alloHCT
compared with the late p-alloHCT group. Duval et al. (Center
for International Blood andMarrow Transplant Research) [5]
and others [8,16] developed scoring systems to predict the
survival of AML patients with active disease undergoing
alloHCT. The observed OS of p-alloHCT patients when
analyzed by the Duval score was comparable with reported
values, although the observed survival for patients with
intermediate and high Duval scores was slightly below
expected, possibly because of the small number of obser-
vations. These ﬁndings suggest p-alloHCT may be an effec-
tive strategy in patients with lower Duval scores. For
patients with intermediate and high Duval scores, the
addition of novel agents to induction chemotherapy or
conditioning to achieve better disease control before
alloHCT may be beneﬁcial.
The presence of a refractory or hypoplastic marrow
immediately before alloHCT would normally preclude
alloHCT because of the perceived excess toxicity and futility
of alloHCT in the setting of uncontrolled disease. Indeed, in a
large retrospective study of 67 patients younger than
40 years old with an HLA matched donor, only 30 received
alloHCT. The most common reasons for not receiving trans-
plant were primary refractory disease (n ¼ 15) and short
duration of CR< 3 months (n¼ 9) [17]. Other reasons for not
receiving transplant were the patient declined transplant
(n ¼ 7), no documented reason (n ¼ 5), and the donor was
not medically suitable (n ¼ 1). In our study, 30 of 72transplant-eligible patients were predicted to have a low
probability of achieving CR, and only 1 of 30 achieved a CR
before transplant. These 30 patients are comparable with the
22 of 67 (33%) refractory or short CR duration patients
referenced above. In contrast, these patients were able to
proceed to alloHCT with early p-alloHCT being feasible and
comparable in safety and efﬁcacy to late p-alloHCT. Notably,
many patients in our study did not receive alloHCT because
G.L. Chen et al. / Biol Blood Marrow Transplant 20 (2014) 1369e13741374of excess toxicity from reinduction chemotherapy, again
suggesting that identiﬁcation of less toxic and more effective
salvage reinduction chemotherapy agents may further
extend the availability of alloHCT.
In summary, our study suggests that preemptive early
alloHCT before count recovery within 4 weeks of reinduction
chemotherapy in high-risk AML patients with hypoplastic or
refractory bonemarrows is feasible, has acceptablemortality,
and results in clinical outcomes not signiﬁcantly different
from similar patients transplanted after count recovery. Early
p-alloHCT may be preferable to late p-alloHCT because
residual disease previously minimized with induction
chemotherapy can rapidly progress in a short time interval.
Although early p-alloHCT requires close coordination
between leukemia and transplant programs and may be
more difﬁcult in the unrelated donor setting or in patients
receiving leukemia therapy at a distance from the transplant
center, these difﬁculties are offset by the ability to offer a
potentially life-saving treatment to patients with few
options.
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